Cargando…
OR27-04 Efficacy And Safety Results From The Randomized, Placebo-controlled Multicenter Trial With Teprotumumab In Chronic-Low Clinical Activity Score Thyroid Eye Disease Patients
Disclosure: R.S. Douglas: Consulting Fee; Self; Horizon, Immunovant, Viridian. Research Investigator; Self; Horizon. S. Couch: Research Investigator; Self; Horizon. S.T. Wester: Advisory Board Member; Self; Horizon. Consulting Fee; Self; Immunovant, Sling. Research Investigator; Self; Horizon. B.T....
Autores principales: | Douglas, Raymond S, Couch, Steven, Wester, Sara T, Fowler, Brian T, Liu, Catherine, Subramanian, Prem, Tang, Rosa, Nguyen, Quang T, Maamari, Robi N, Hsu, Kate, Karon, Michael, Stan, Marius |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10554583/ http://dx.doi.org/10.1210/jendso/bvad114.2055 |
Ejemplares similares
-
SAT455 A Randomized, Quadruple-masked, Placebo-controlled, Multicenter Trial To Evaluate The Efficacy And Safety Of Teprotumumab In Patients With Chronic (Inactive/Low CAS) Thyroid Eye Disease
por: Douglas, Raymond S, et al.
Publicado: (2023) -
FRI572 Teprotumumab In Unexplored Presentation Of Thyroid Eye Disease
por: Torres Torres, Marina T, et al.
Publicado: (2023) -
Hearing Loss and Teprotumumab
por: Kossler, Andrea, et al.
Publicado: (2021) -
PSAT265 Blood Glucose in Thyroid Eye Disease (TED) in Patients treated with Teprotumumab: Clinical Trials Data
por: Smith, Terry J, et al.
Publicado: (2022) -
RF35 | PSAT263 Efficacy of Teprotumumab for Thyroid Eye Disease in Hypothyroid Patients
por: Smith, Terry J, et al.
Publicado: (2022)